Two months after revealing that a heart failure collaboration with Bristol Myers Squibb had hit the buffers, Ambrx Biopharma has lost its CEO and announced a “strategic review” of its pipeline.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,